What is the appropriate workup for an elevated right ventricular systolic pressure?

Workup for Elevated RVSP

When echocardiography reveals an elevated right ventricular systolic pressure (RVSP), proceed with a systematic diagnostic algorithm to determine the underlying cause and severity of pulmonary hypertension, starting with confirmatory echocardiographic assessment, followed by targeted testing to classify the PH type, and culminating in right heart catheterization when treatment decisions are needed.

Initial Echocardiographic Assessment

The first step is to verify the RVSP measurement and assess for additional echocardiographic signs of pulmonary hypertension 1, 2:

• Confirm the tricuspid regurgitation velocity measurement - Use the peak TR velocity (not the estimated PASP) as the primary variable, as this reduces measurement error amplification 1
• Estimate right atrial pressure based on inferior vena cava characteristics:
  • IVC <2.1 cm with >50% collapse = RAP 3 mmHg (0-5 mmHg)
  • IVC >2.1 cm with <50% collapse = RAP 15 mmHg (10-20 mmHg)
  • Intermediate findings = RAP 8 mmHg (5-10 mmHg) 1
• Look for additional PH signs: right atrial enlargement, right ventricular enlargement, abnormal septal motion, pericardial effusion, dilated pulmonary artery 3, 1

Important context: Normal RVSP varies by age. In patients <50 years, normal range is 16-39 mmHg; ages 50-75 years: 15-45 mmHg; >75 years: 17-52 mmHg 4. An ePASP >30 mmHg warrants further evaluation regardless of age 5.

Pivotal Diagnostic Tests (Required for All Patients)

These tests must be performed to establish diagnosis and exclude secondary causes 6, 3:

1. Electrocardiogram

• Screen for right atrial enlargement, right axis deviation, RV hypertrophy 3
• Provides prognostic information but lacks sensitivity for screening 3

2. Chest Radiograph

• Assess for enlarged pulmonary arteries, cardiomegaly, parenchymal lung disease 3
• Look for features of pulmonary venous congestion, hyperinflation, or interstitial disease 3

3. Ventilation-Perfusion (V/Q) Scan

• Essential to rule out chronic thromboembolic pulmonary hypertension (CTEPH) - a normal scan effectively excludes CTEPH 3, 5
• Do NOT use CT angiography alone to exclude CTEPH 3

4. Pulmonary Function Tests with DLCO

• Evaluate for obstructive or restrictive lung disease 3
• Arterial blood gas analysis to assess oxygenation 3

5. Overnight Oximetry or Polysomnography

• Screen for sleep-disordered breathing, which is present in 70-80% of PAH patients 1

6. Serologic Testing

• HIV testing 3
• Connective tissue disease screening (ANA, with additional serologies if positive) 3
• Liver function tests if portopulmonary hypertension suspected 6

Contingent Tests (Performed Based on Initial Findings)

If V/Q scan shows perfusion defects:

• Pulmonary angiography required for definitive CTEPH diagnosis and operability assessment 3

If left heart disease suspected:

• Comprehensive echocardiographic assessment of:
  • LV systolic and diastolic function 3
  • Left-sided chamber enlargement 3
  • Valvular heart disease (especially mitral and aortic) 3, 7
• Consider contrast echocardiography to evaluate for intracardiac shunts 3

If parenchymal lung disease identified:

• High-resolution chest CT to characterize extent of emphysema or interstitial disease 1

Right Heart Catheterization

RHC is mandatory before initiating PAH-specific therapy 8, 3, 9:

Indications:

• Intermediate or high echocardiographic probability of PH when treatment is being considered 2
• Confirm presence of PH (mPAP >20 mmHg per 2018 definition) 9
• Classify PH type (precapillary vs. postcapillary) 9
• Measure pulmonary vascular resistance (PVR ≥2 Wood units defines precapillary PH per 2024 guidelines) 9
• Perform vasoreactivity testing in PAH patients (inhaled nitric oxide 20-40 ppm) 9

Key measurements:

• Right atrial pressure, RV pressure, pulmonary artery pressure (systolic, diastolic, mean)
• Pulmonary arterial wedge pressure (PAWP ≤15 mmHg defines precapillary PH)
• Cardiac output (thermodilution or Fick method)
• Calculate PVR = (mPAP - PAWP)/cardiac output 9

Common Pitfalls to Avoid

1. Do not rely solely on estimated PASP - Use peak TR velocity and look for additional echocardiographic signs of PH 1
2. Do not skip V/Q scanning - CT angiography alone misses CTEPH 3
3. Do not assume fixed RAP of 5 or 10 mmHg - Estimate based on IVC characteristics 1
4. Do not initiate PAH-specific therapy without RHC confirmation - Echocardiography alone is insufficient for treatment decisions 6, 2
5. Recognize that absence of measurable TR does not exclude PH - Look for short pulmonary acceleration time, RV hypertrophy/dilation 5

Risk Stratification

Even mildly elevated ePASP (30-40 mmHg) carries significant mortality risk and warrants complete evaluation 5. Five-year mortality with ePASP 30-32 mmHg is 28.9%, substantially higher than those with normal pressures 5.